UFC heavyweight fighter Carlos Felipe was suspended 18 months due to a positive drug test for a steroid, the Nevada State Athletic Commission (NSAC) announced Tuesday.
Felipe tested positive for the anabolic agent boldenone and its metabolites in relation to his UFC Fight Night co-main event with Andrei Arlovski on Oct. 16, NSAC executive director Jeff Mullen said.
The suspension will be retroactive to the fight date, so Felipe will be eligible to return in April 2023. Felipe was also fined 15% of his purse, plus attorney fees. Arlovski won the fight via unanimous decision.
Felipe’s manager, Tiago Okamura, said in a statement that news of the positive drug test was a “huge surprise” and that Felipe did not knowingly take the banned substance. Okamura said Felipe accepted an adjudication agreement for an 18-month suspension with the NSAC because legal costs would have approached $10,000 if Felipe continued to fight the charge and he could not afford that.
“Unfortunately, the amount needed to put up a proper defense along with the testing of all products was not something realistic for Carlos,” Okamura said.
The NSAC could have suspended Felipe 24 months, but Felipe’s team was able to broker a lesser ban by entering into the adjudication agreement, Okamura said.
This is Felipe’s second run-in with doping issues. His UFC debut was delayed by a two-year suspension from USADA, the UFC’s anti-doping partner, after a positive test for the steroid stanozolol.
USADA spokesperson Adam Woullard declined to comment on the matter, and it is unclear how USADA will handle the current case. Okamura said Felipe only failed the NSAC drug test and not any USADA tests.
“If he was ever to test positive again in a USADA test, he would be penalized with a four-year suspension,” Okamura said. “Once the suspension was complete and he was re-signed to the UFC, Carlos knew he could never slip up again or the consequences would be dire. So with that in mind, the new positive result was a huge surprise.”